ARTICLE BY LOUIS

• Lonza Bets On Biologics. What's It Mean For You?

  6/26/2025

  It’s a large and universally recognizable CDMO, so this matters. Swiss-based powerhouse Lonza will increase its focus on biologics, and “advanced synthesis” including for antibody-drug conjugates (ADCs), cell and gene therapies (CGT), and mRNA therapeutics. Will other CDMOs follow suit? What's this say about the future of development outsourcing and our industry? 

• Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs

  4/23/2025

  According to Global Data, the total deal value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. This is an area way upstream of the current tariff focus on manufacturing. But how this R&D trend and those tariffs play out will impact your U.S.-based CDMOs.

• View From Tokyo: Rise Of The “Values” Chain

  5/15/2020

  The Wuhan coronavirus outbreak has brokered a virulent "value" chain debate around the world, including a global CDMO's CEO situated in Tokyo. 

• A COVID-19 Vaccine, Outsourcing, And Made In The USA

  4/27/2020

  That’s an unwieldy title for an editorial. But we’ll bundle those three components quickly, thanks to U.S.-based GeoVax Labs CEO David Dodd. He's the quintessential professional to assist readers in assessing and contemplating current and future realities.

• Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance

  2/5/2015

  Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.

• Biosimilars Part 2: It's All About Dollars Now

  2/2/2015

  Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.

• Biosimilars: A Brief Manifesto of Morality And Markets

  1/26/2015

  As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.

• A Global Forum For Outsourcing (With Simple Objectives)

  9/24/2014

  Perhaps the best advice I’ve heard regarding industry conferences is twofold: first, make sure you attend, and second, keep your objectives for attending simple.

• Serial Entrepreneur Points To Initial Funding Sources For Biotechs

  9/24/2014

  Kevin Judice lists himself on LinkedIn as “Entrepreneur.” Perhaps he has to; there just isn’t enough space to include the three companies he recently started and at which he concurrently is employed as CEO or CSO.